133
Views
21
CrossRef citations to date
0
Altmetric
Original

Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus

, , , , , , , , , & show all
Pages 549-555 | Published online: 07 Jul 2009

References

  • Karim MY, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Update on therapy-thalidomide in the treatment of lupus. Lupus 2001; 10: 188–192
  • Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969–979
  • Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Peserico A, Doria A. TNF-α is expressed in refractory skin lesions from subacute cutaneous lupus erythematosus patients. Ann Rheum Dis 2005; in press.
  • Sheskin J. The treatment of lepra reaction in lepromatosus leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980; 19: 318–322
  • Wulff CH, Hoyer H, Asboc-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475–480
  • Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461–466
  • Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients. J Investig Dermatol 2002; 119: 1020–1026
  • Fullerton PM, O'Sullivan J. Thalidomide neuropathy; a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiat 1968; 31: 543–551
  • Calabrese L, Fleischer AB, Jr. Thalidomide: Current and potential clinical applications. Am J Med 2000; 108: 487–495
  • Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872–1875
  • Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828–832
  • Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66–69
  • Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60: 337–340
  • Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
  • American Rheumatism Association Glossary Committee. Dictionary of the rheumatic disease: Signs and symptoms. Conctact Associates International, Bayport, New York 1982; Vol. 1: 1–80, 1st edn.
  • Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1–9
  • Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 541–547
  • Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369
  • Dyck PJ. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle Nerve 1988; 11: 21–32
  • Notermans NC, Wokke JH, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994; 117: 1385–1393
  • van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–607
  • Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghirardello A, Zampieri S, Gambari PF, Perini G. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology 2004; 43: 1574–1579
  • Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, Zampieri S, Della Libera S, Perini G, Todesco S. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants. Rheumatology 2004; 43: 1580–1586
  • Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB, Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139: 50–54
  • Lagueny A, Rommel A, Vignolly B, et al. Thalidomide neuropathy: An electrophysiologic study. Muscle Nerve 1986; 9: 837–844
  • Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120: 338–341
  • Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: A ganglionopathy?. Neurology 2003; 60: 877–878
  • Hess CW, Hunziker T, Kupfer A, Ludin HP. Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233: 83–89
  • Harland CC, Steventon GB, Marsden JR. Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995; 49: 1–6
  • Hamanoue M, Middleton G, Wyatt S, Jaffray E, Hay RT, Davies AM. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 1999; 14: 28–40
  • Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide and Thrombosis. Ann Dermatol Venereol 2000; 127: 171–174
  • Ghirardello A, Doria A, Ruffatti A, et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Are they specific tools for the diagnosis of aPL syndrome in SLE?. Ann Rheum Dis 1994; 53: 40–42
  • Doria A, Ghirardello A, Boscaro M, et al. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy. Rheumatol Int 1995; 14: 207–211
  • Piette J-C, Sbaï A, Francès C. Warning: Thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 2002; 11: 67–70

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.